This newsletter presents you the following presentations:
1. Comparison of two bevacizumab containing regimens in the first-line therapy of HER-negative metastatic
breast cancer
2. The incidence of central nervous system metastases in patients with metastatic breast cancer treated
with lapatinib-capecitabine or trastuzumab-capecitabine: results from the CEREBEL study
3. Confirmed survival benefit of trastuzumab emtansine (T-DM1) over capecitabine plus lapatinib: updated
results from the EMILIA trial
4. Docetaxel and paclitaxel based chemotherapy regimens have a comparable efficacy in patients with
metastatic breast cancer